RESUMO
Machine learning has become a crucial tool in drug discovery and chemistry at large, e.g., to predict molecular properties, such as bioactivity, with high accuracy. However, activity cliffsâpairs of molecules that are highly similar in their structure but exhibit large differences in potencyâhave received limited attention for their effect on model performance. Not only are these edge cases informative for molecule discovery and optimization but also models that are well equipped to accurately predict the potency of activity cliffs have increased potential for prospective applications. Our work aims to fill the current knowledge gap on best-practice machine learning methods in the presence of activity cliffs. We benchmarked a total of 24 machine and deep learning approaches on curated bioactivity data from 30 macromolecular targets for their performance on activity cliff compounds. While all methods struggled in the presence of activity cliffs, machine learning approaches based on molecular descriptors outperformed more complex deep learning methods. Our findings highlight large case-by-case differences in performance, advocating for (a) the inclusion of dedicated "activity-cliff-centered" metrics during model development and evaluation and (b) the development of novel algorithms to better predict the properties of activity cliffs. To this end, the methods, metrics, and results of this study have been encapsulated into an open-access benchmarking platform named MoleculeACE (Activity Cliff Estimation, available on GitHub at: https://github.com/molML/MoleculeACE). MoleculeACE is designed to steer the community toward addressing the pressing but overlooked limitation of molecular machine learning models posed by activity cliffs.
Assuntos
Descoberta de Drogas , Aprendizado de Máquina , Relação Estrutura-Atividade , Modelos Moleculares , AlgoritmosRESUMO
Chemical language models (CLMs) can be employed to design molecules with desired properties. CLMs generate new chemical structures in the form of textual representations, such as the simplified molecular input line entry system (SMILES) strings. However, the quality of these de novo generated molecules is difficult to assess a priori. In this study, we apply the perplexity metric to determine the degree to which the molecules generated by a CLM match the desired design objectives. This model-intrinsic score allows identifying and ranking the most promising molecular designs based on the probabilities learned by the CLM. Using perplexity to compare "greedy" (beam search) with "explorative" (multinomial sampling) methods for SMILES generation, certain advantages of multinomial sampling become apparent. Additionally, perplexity scoring is performed to identify undesired model biases introduced during model training and allows the development of a new ranking system to remove those undesired biases.
Assuntos
Idioma , Modelos Químicos , ProbabilidadeRESUMO
Chemical language models enable deâ novo drug design without the requirement for explicit molecular construction rules. While such models have been applied to generate novel compounds with desired bioactivity, the actual prioritization and selection of the most promising computational designs remains challenging. Herein, we leveraged the probabilities learnt by chemical language models with the beam search algorithm as a model-intrinsic technique for automated molecule design and scoring. Prospective application of this method yielded novel inverse agonists of retinoic acid receptor-related orphan receptors (RORs). Each design was synthesizable in three reaction steps and presented low-micromolar to nanomolar potency towards RORγ. This model-intrinsic sampling technique eliminates the strict need for external compound scoring functions, thereby further extending the applicability of generative artificial intelligence to data-driven drug discovery.
Assuntos
Automação , Produtos Biológicos/farmacologia , Desenho de Fármacos , Receptores do Ácido Retinoico/agonistas , Algoritmos , Produtos Biológicos/síntese química , Produtos Biológicos/química , Humanos , Ligantes , Estrutura MolecularRESUMO
Nuclear receptors (NRs) are key regulators of human health and constitute a relevant target for medicinal chemistry applications as well as for toxicological risk assessment. Several open databases dedicated to small molecules that modulate NRs exist; however, depending on their final aim (i.e., adverse effect assessment or drug design), these databases contain a different amount and type of annotated molecules, along with a different distribution of experimental bioactivity values. Stemming from these considerations, in this work we aim to provide a unified dataset, NURA (NUclear Receptor Activity) dataset, collecting curated information on small molecules that modulate NRs, to be intended for both pharmacological and toxicological applications. NURA contains bioactivity annotations for 15,247 molecules and 11 selected NRs, and it was obtained by integrating and curating data from toxicological and pharmacological databases (i.e., Tox21, ChEMBL, NR-DBIND and BindingDB). Our results show that NURA dataset is a useful tool to bridge the gap between toxicology- and medicinal-chemistry-related databases, as it is enriched in terms of number of molecules, structural diversity and covered atomic scaffolds compared to the single sources. To the best of our knowledge, NURA dataset is the most exhaustive collection of small molecules annotated for their modulation of the chosen nuclear receptors. NURA dataset is intended to support decision-making in pharmacology and toxicology, as well as to contribute to data-driven applications, such as machine learning. The dataset and the data curation pipeline can be downloaded free of charge on Zenodo at the following DOI: https://doi.org/10.5281/zenodo.3991561.
Assuntos
Bases de Dados Factuais , Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos , Química Farmacêutica/métodos , Simulação por Computador , Coleta de Dados , Interpretação Estatística de Dados , Avaliação Pré-Clínica de Medicamentos , Humanos , Técnicas In Vitro , Modelos Moleculares , Bibliotecas de Moléculas Pequenas , Software , Toxicologia/métodosRESUMO
Recurrent neural networks (RNNs) are able to generate de novo molecular designs using simplified molecular input line entry systems (SMILES) string representations of the chemical structure. RNN-based structure generation is usually performed unidirectionally, by growing SMILES strings from left to right. However, there is no natural start or end of a small molecule, and SMILES strings are intrinsically nonunivocal representations of molecular graphs. These properties motivate bidirectional structure generation. Here, bidirectional generative RNNs for SMILES-based molecule design are introduced. To this end, two established bidirectional methods were implemented, and a new method for SMILES string generation and data augmentation is introduced-the bidirectional molecule design by alternate learning (BIMODAL). These three bidirectional strategies were compared to the unidirectional forward RNN approach for SMILES string generation, in terms of the (i) novelty, (ii) scaffold diversity, and (iii) chemical-biological relevance of the computer-generated molecules. The results positively advocate bidirectional strategies for SMILES-based molecular de novo design, with BIMODAL showing superior results to the unidirectional forward RNN for most of the criteria in the tested conditions. The code of the methods and the pretrained models can be found at URL https://github.com/ETHmodlab/BIMODAL.
Assuntos
Redes Neurais de ComputaçãoRESUMO
Consensus strategies have been widely applied in many different scientific fields, based on the assumption that the fusion of several sources of information increases the outcome reliability. Despite the widespread application of consensus approaches, their advantages in quantitative structure-activity relationship (QSAR) modeling have not been thoroughly evaluated, mainly due to the lack of appropriate large-scale data sets. In this study, we evaluated the advantages and drawbacks of consensus approaches compared to single classification QSAR models. To this end, we used a data set of three properties (androgen receptor binding, agonism, and antagonism) for approximately 4000 molecules with predictions performed by more than 20 QSAR models, made available in a large-scale collaborative project. The individual QSAR models were compared with two consensus approaches, majority voting and the Bayes consensus with discrete probability distributions, in both protective and nonprotective forms. Consensus strategies proved to be more accurate and to better cover the analyzed chemical space than individual QSARs on average, thus motivating their widespread application for property prediction. Scripts and data to reproduce the results of this study are available for download.
Assuntos
Relação Quantitativa Estrutura-Atividade , Teorema de Bayes , Consenso , Reprodutibilidade dos TestesRESUMO
Chromatographic profiles of primary essential oils (EO) deliver valuable authentic information about composition and compound pattern. Primary EOs obtained from Pinus sylvestris L. (PS) from different global origins were analyzed using gas chromatography coupled to a flame ionization detector (GC-FID) and identified by GC hyphenated to mass spectrometer (GC-MS). A primary EO of PS was characterized by a distinct sesquiterpene pattern followed by a diterpene profile containing diterpenoids of the labdane, pimarane or abietane type. Based on their sesquiterpene compound patterns, primary EOs of PS were separated into their geographical origin using component analysis. Furthermore, differentiation of closely related pine EOs by partial least square discriminant analysis proved the existence of a primary EO of PS. The developed and validated PLS-DA model is suitable as a screening tool to assess the correct chemotaxonomic identification of a primary pine EOs as it classified all pine EOs correctly.
Assuntos
Óleos Voláteis/análise , Pinus sylvestris/química , Análise Discriminante , Diterpenos/análise , Diterpenos/química , Cromatografia Gasosa-Espectrometria de Massas , Estrutura Molecular , Óleos de Plantas/análise , Sesquiterpenos/análise , Sesquiterpenos/químicaRESUMO
The nuclear androgen receptor (AR) is one of the most relevant biological targets of Endocrine Disrupting Chemicals (EDCs), which produce adverse effects by interfering with hormonal regulation and endocrine system functioning. This paper describes novel in silico models to identify organic AR modulators in the context of the Collaborative Modeling Project of Androgen Receptor Activity (CoMPARA), coordinated by the National Center of Computational Toxicology (U.S. Environmental Protection Agency). The collaborative project involved 35 international research groups to prioritize the experimental tests of approximatively 40k compounds, based on the predictions provided by each participant. In this paper, we describe our machine learning approach to predict the binding to AR, which is based on a consensus of a multivariate Bernoulli Naive Bayes, a Random Forest, and N-Nearest Neighbor classification models. The approach was developed in compliance with the Organization of Economic Cooperation and Development (OECD) principles, trained on 1687 ToxCast molecules classified according to 11 in vitro assays, and further validated on a set of 3,882 external compounds. The models provided robust and reliable predictions and were used to gather novel data-driven insights on the structural features related to AR binding, agonism, and antagonism.
Assuntos
Antagonistas de Receptores de Andrógenos/farmacologia , Androgênios/farmacologia , Disruptores Endócrinos/farmacologia , Aprendizado de Máquina , Receptores Androgênicos/metabolismo , Antagonistas de Receptores de Andrógenos/química , Androgênios/química , Descoberta de Drogas , Disruptores Endócrinos/química , Humanos , Simulação de Acoplamento Molecular , Ligação Proteica , SoftwareRESUMO
Drug discovery benefits from computational models aiding the identification of new chemical matter with bespoke properties. The field of de novo drug design has been particularly revitalized by adaptation of generative machine learning models from the field of natural language processing. These deep neural network models are trained on recognizing molecular structures and generate new molecular entities without relying on pre-determined sets of molecular building blocks and chemical transformations for virtual molecule construction. Implicit representation of chemical knowledge provides an alternative to formulating the molecular design task in terms of the established, explicit chemical vocabulary. Here, we review de novo molecular design approaches from the field of 'artificial intelligence', focusing on instances of deep generative models, and highlight the prospective application of long short-term memory models to hit and lead finding in medicinal chemistry.
Assuntos
Memória de Curto Prazo , Desenho de Fármacos , Aprendizado de Máquina , Redes Neurais de Computação , Estudos ProspectivosRESUMO
Validation is an essential step of QSAR modeling, and it can be performed by both internal validation techniques (e.g., cross-validation, bootstrap) or by an external set of test objects, that is, objects not used for model development and/or optimization. The evaluation of model predictive ability is then completed by comparing experimental and predicted values of test molecules. When dealing with quantitative QSAR models, validation results are generally expressed in terms of Q2 metrics. In this work, four fundamental mathematical principles, which should be respected by any Q2 metric, are introduced. Then, the behavior of five different metrics (QF12, QF22, QF32, QCCC2, and QRm2) is compared and critically discussed. The conclusions highlight that only the QF32 metric satisfies all the stated conditions, while the remaining metrics show different theoretical flaws.
Assuntos
Algoritmos , Relação Quantitativa Estrutura-Atividade , Simulação por Computador , Modelos QuímicosRESUMO
Expert systems are a rational integration of several models that generally aim to exploit their advantages and overcome their drawbacks. This work is founded on our previously published Quantitative Structure-Activity Relationship (QSAR) classification scheme, which detects compounds whose Bioconcentration Factor (BCF) is (1) well predicted by the octanol-water partition coefficient (KOW), (2) underestimated by KOW or (3) overestimated by KOW. The classification scheme served as the starting point to identify and combine the best BCF model for each class among three VEGA models and one KOW-based equation. The rationalized model integration showed stability and surprising performance on unknown data when compared with benchmark BCF models. Model simplicity, transparency and mechanistic interpretation were fostered in order to allow for its application and acceptance within the REACH framework.
Assuntos
Modelos Teóricos , Relação Quantitativa Estrutura-Atividade , 1-Octanol/química , União Europeia , Regulamentação Governamental , Substâncias Perigosas/química , Água/químicaRESUMO
Cytochromes P450 (CYP) are the main actors in the oxidation of xenobiotics and play a crucial role in drug safety, persistence, bioactivation, and drug-drug/food-drug interaction. This work aims to develop Quantitative Structure-Activity Relationship (QSAR) models to predict the drug interaction with two of the most important CYP isoforms, namely 2C9 and 3A4. The presented models are calibrated on 9122 drug-like compounds, using three different modelling approaches and two types of molecular description (classical molecular descriptors and binary fingerprints). For each isoform, three classification models are presented, based on a different approach and with different advantages: (1) a very simple and interpretable classification tree; (2) a local (k-Nearest Neighbor) model based classical descriptors and; (3) a model based on a recently proposed local classifier (N-Nearest Neighbor) on binary fingerprints. The salient features of the work are (1) the thorough model validation and the applicability domain assessment; (2) the descriptor interpretation, which highlighted the crucial aspects of P450-drug interaction; and (3) the consensus aggregation of models, which largely increased the prediction accuracy.
Assuntos
Inibidores do Citocromo P-450 CYP2C9/farmacologia , Citocromo P-450 CYP2C9/química , Inibidores do Citocromo P-450 CYP3A/farmacologia , Citocromo P-450 CYP3A/química , Relação Quantitativa Estrutura-Atividade , Animais , Simulação por Computador , Citocromo P-450 CYP2C9/metabolismo , Inibidores do Citocromo P-450 CYP2C9/química , Citocromo P-450 CYP3A/metabolismo , Inibidores do Citocromo P-450 CYP3A/química , Humanos , Ligação ProteicaRESUMO
Generative deep learning is reshaping drug design. Chemical language models (CLMs) - which generate molecules in the form of molecular strings - bear particular promise for this endeavor. Here, we introduce a recent deep learning architecture, termed Structured State Space Sequence (S4) model, into de novo drug design. In addition to its unprecedented performance in various fields, S4 has shown remarkable capabilities to learn the global properties of sequences. This aspect is intriguing in chemical language modeling, where complex molecular properties like bioactivity can 'emerge' from separated portions in the molecular string. This observation gives rise to the following question: Can S4 advance chemical language modeling for de novo design? To provide an answer, we systematically benchmark S4 with state-of-the-art CLMs on an array of drug discovery tasks, such as the identification of bioactive compounds, and the design of drug-like molecules and natural products. S4 shows a superior capacity to learn complex molecular properties, while at the same time exploring diverse scaffolds. Finally, when applied prospectively to kinase inhibition, S4 designs eight of out ten molecules that are predicted as highly active by molecular dynamics simulations. Taken together, these findings advocate for the introduction of S4 into chemical language modeling - uncovering its untapped potential in the molecular sciences.
Assuntos
Simulação de Dinâmica Molecular , Desenho de Fármacos , Aprendizado Profundo , Modelos Químicos , Descoberta de Drogas/métodos , Produtos Biológicos/químicaRESUMO
Deep learning is becoming increasingly relevant in drug discovery, from de novo design to protein structure prediction and synthesis planning. However, it is often challenged by the small data regimes typical of certain drug discovery tasks. In such scenarios, deep learning approaches-which are notoriously 'data-hungry'-might fail to live up to their promise. Developing novel approaches to leverage the power of deep learning in low-data scenarios is sparking great attention, and future developments are expected to propel the field further. This mini-review provides an overview of recent low-data-learning approaches in drug discovery, analyzing their hurdles and advantages. Finally, we venture to provide a forecast of future research directions in low-data learning for drug discovery.
Assuntos
Aprendizado Profundo , Descoberta de Drogas , Descoberta de Drogas/métodos , Humanos , Proteínas/química , Proteínas/metabolismoRESUMO
Natural products are a diverse class of compounds with promising biological properties, such as high potency and excellent selectivity. However, they have different structural motifs than typical drug-like compounds, e.g., a wider range of molecular weight, multiple stereocenters and higher fraction of sp3-hybridized carbons. This makes the encoding of natural products via molecular fingerprints difficult, thus restricting their use in cheminformatics studies. To tackle this issue, we explored over 30 years of research to systematically evaluate which molecular fingerprint provides the best performance on the natural product chemical space. We considered 20 molecular fingerprints from four different sources, which we then benchmarked on over 100,000 unique natural products from the COCONUT (COlleCtion of Open Natural prodUcTs) and CMNPD (Comprehensive Marine Natural Products Database) databases. Our analysis focused on the correlation between different fingerprints and their classification performance on 12 bioactivity prediction datasets. Our results show that different encodings can provide fundamentally different views of the natural product chemical space, leading to substantial differences in pairwise similarity and performance. While Extended Connectivity Fingerprints are the de-facto option to encoding drug-like compounds, other fingerprints resulted to match or outperform them for bioactivity prediction of natural products. These results highlight the need to evaluate multiple fingerprinting algorithms for optimal performance and suggest new areas of research. Finally, we provide an open-source Python package for computing all molecular fingerprints considered in the study, as well as data and scripts necessary to reproduce the results, at https://github.com/dahvida/NP_Fingerprints .
RESUMO
INTRODUCTION: Janus kinase (JAK) inhibitors were recently identified as promising drug candidates for repurposing in Alzheimer's disease (AD) due to their capacity to suppress inflammation via modulation of JAK/STAT signaling pathways. Besides interaction with primary therapeutic targets, JAK inhibitor drugs frequently interact with unintended, often unknown, biological off-targets, leading to associated effects. Nevertheless, the relevance of JAK inhibitors' off-target interactions in the context of AD remains unclear. METHODS: Putative off-targets of baricitinib and tofacitinib were predicted using a machine learning (ML) approach. After screening scientific literature, off-targets were filtered based on their relevance to AD. Targets that had not been previously identified as off-targets of baricitinib or tofacitinib were subsequently tested using biochemical or cell-based assays. From those, active concentrations were compared to bioavailable concentrations in the brain predicted by physiologically based pharmacokinetic (PBPK) modeling. RESULTS: With the aid of ML and in vitro activity assays, we identified two enzymes previously unknown to be inhibited by baricitinib, namely casein kinase 2 subunit alpha 2 (CK2-α2) and dual leucine zipper kinase (MAP3K12), both with binding constant (K d) values of 5.8 µM. Predicted maximum concentrations of baricitinib in brain tissue using PBPK modeling range from 1.3 to 23 nM, which is two to three orders of magnitude below the corresponding binding constant. CONCLUSION: In this study, we extended the list of baricitinib off-targets that are potentially relevant for AD progression and predicted drug distribution in the brain. The results suggest a low likelihood of successful repurposing in AD due to low brain permeability, even at the maximum recommended daily dose. While additional research is needed to evaluate the potential impact of the off-target interaction on AD, the combined approach of ML-based target prediction, in vitro confirmation, and PBPK modeling may help prioritize drugs with a high likelihood of being effectively repurposed for AD. Highlights: This study explored JAK inhibitors' off-targets in AD using a multidisciplinary approach.We combined machine learning, in vitro tests, and PBPK modelling to predict and validate new off-target interactions of tofacitinib and baricitinib in AD.Previously unknown inhibition of two enzymes (CK2-a2 and MAP3K12) by baricitinib were confirmed using in vitro experiments.Our PBPK model indicates that baricitinib low brain permeability limits AD repurposing.The proposed multidisciplinary approach optimizes drug repurposing efforts in AD research.
RESUMO
Generative deep learning is accelerating de novo drug design, by allowing the generation of molecules with desired properties on demand. Chemical language models - which generate new molecules in the form of strings using deep learning - have been particularly successful in this endeavour. Thanks to advances in natural language processing methods and interdisciplinary collaborations, chemical language models are expected to become increasingly relevant in drug discovery. This minireview provides an overview of the current state-of-the-art of chemical language models for de novo design, and analyses current limitations, challenges, and advantages. Finally, a perspective on future opportunities is provided.